Innovation 2 Translation 2026: What Shapes the Path to Translation?

A scientific discovery is only the beginning... what happens next can take many forms.

A discovery might be licensed, developed into a company, attract investment or take an entirely different path. Innovation 2 Translation 2026 brings together researchers, biotech leaders, investors and the broader life sciences ecosystem to unpack the choices, opportunities and challenges along the way.

Through presentations, panel discussions, and a live investment review, hear different perspectives, ask questions and connect with others working across the life sciences ecosystem, with plenty of opportunity to network throughout the event.

Topics include:

• Paths to translation: Hear from company builders about the different routes from scientific discovery to building and growing a biotech company.

• Global ecosystems: Explore how the UK, US and Europe shape the journey from discovery through funding, talent, university incentives, licensing and government support.

• What’s hot in science: Look at the emerging technologies and scientific trends creating new opportunities in biotech.

• AI and investment: Put VCs in the hot seat and explore how AI could change the way investors assess opportunities and make investment decisions.

There is no single path from science to impact. Innovation 2 Translation 2026 explores the different routes, decisions and turning points that shape what happens next.

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture and industrial chemicals, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit www.twistbioscience.com.

Moderna is biotechnology company focused on the development of mRNA medicines. Through the advancement of its mRNA technology platform, Moderna is exploring new approaches to how medicines are made, with the aim of improving prevention and treatment of diseases. Since its founding, Moderna's mRNA platform has supported the research and development of vaccines and therapeutics across infectious diseases, cancer and rare diseases. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.

Jointly formed by the University of Melbourne and Monash University, with support from the Victorian State Government, BioCurate identifies promising biomedical research discoveries and manages their translation into high-quality pre-clinical candidates for novel human therapeutics. With a team of experts who bring decades of scientific and commercial expertise, BioCurate provides a critical bridge between academia and industry to grow the Victorian and Australian biotech sector by increasing the number, quality, and rate of translation of new drug discoveries into medically sound and commercially attractive, investable projects.

Jumar Bioincubator serves as a ‘first home’ for 30+ biotech startups in Australia, offering affordable lab and office space alongside practical support to help unlock the potential of early scientific discoveries. Companies in residence become part of a vibrant community, with access to world-class facilities, a dedicated team to lean on, as well as curated entrepreneurial training and events. Established by CSL, WEHI and the University of Melbourne, with backing from innovation investor Breakthrough Victoria and operator Cicada Innovations, our mission is to connect early-stage biotech ventures with the support they need to progress discoveries towards real-world treatments and therapies, build a critical mass of scientists with the knowledge and confidence to run successful biomedical ventures - and the power to influence and impact global health outcomes.

Melbourne Therapeutics (MTx) is a network of academic and industry organisations working together to advance novel medicine development from biomedical discoveries across Melbourne’s biomedical precinct. MTx brings organisations together to foster collaboration, strengthen translation and entrepreneurship, and build capability in therapeutic development. Through joint programs, information exchange and partnerships, MTx advocates for the precinct’s strengths in drug discovery and development and identifies gaps in the therapeutic development pipeline, helping develop or facilitate solutions that move local biomedical discoveries towards new medicines.

• You may be photographed or videoed while attending this event for marketing purposes: please approach the organiser if you have questions, concerns, or do not wish this to happen.

• For security purposes, we kindly ask that all attendees bring a valid government-issued photo ID for registration upon arrival.